Computerized physician order entry‐based system to prevent HBV reactivation in patients treated with biologic agents: The PRESCRIB project

Computerized physician order entry (CPOE) applications are widely used to prevent medical errors. In our center, a CPOE system has been in use since 2009 on both the inpatient and outpatient levels. A new and simple alert was introduced in the CPOE system to notify healthcare providers of the potent...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Hepatology (Baltimore, Md.) Md.), 2014-07, Vol.60 (1), p.106-113
Hauptverfasser: Sampedro, Blanca, Hernández‐López, Cándido, Ferrandiz, José Ramón, Illaro, Aitziber, Fábrega, Emilio, Cuadrado, Antonio, Iruzubieta, Paula, Menéndez, Susana, Cabezas, Joaquín, Crespo, Javier
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 113
container_issue 1
container_start_page 106
container_title Hepatology (Baltimore, Md.)
container_volume 60
creator Sampedro, Blanca
Hernández‐López, Cándido
Ferrandiz, José Ramón
Illaro, Aitziber
Fábrega, Emilio
Cuadrado, Antonio
Iruzubieta, Paula
Menéndez, Susana
Cabezas, Joaquín
Crespo, Javier
description Computerized physician order entry (CPOE) applications are widely used to prevent medical errors. In our center, a CPOE system has been in use since 2009 on both the inpatient and outpatient levels. A new and simple alert was introduced in the CPOE system to notify healthcare providers of the potential risk of viral reactivation when prescribing biological therapies, thereby facilitating the request for a serological profile (hepatitis B surface antigen [HBsAg], anti‐HBc, and anti‐HBs) in patients who have not had these tests. Between May 2012 and May 2013, a total of 1,076 patients undergoing biological treatment were included in the implementation of the CPOE in our hospital, resulting in the identification of 4 HBsAg‐positive and 69 anti‐HBc‐positive/HBsAg‐negative patients, two of them with positive viral loads. Since the implementation of this alert system, over 90% of patients who were prescribed a biological drug (BD) have undergone serological screening to detect hepatitis B virus (HBV) infection. The use of the alert system has increased the screening rate from less than 50% to 94% for HBsAg and from less than 30% to 85% for anti‐HBc in patients for whom a BD is prescribed. Six patients received prophylactic antiviral therapy. No patient had HBV reactivation. Conclusion: This study demonstrates the feasibility of implementing a CPOE system that has allowed our hospital to increase the rate of HBV screening. Its use has facilitated the identification of patients at high risk for HBV reactivation and permitted physicians to prescribe prophylactic measures according to current guidelines. (Hepatology 2014;106–113)
doi_str_mv 10.1002/hep.27103
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1542003561</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1542003561</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4233-63d72e4ccc5c71226f8753b65474202530a74d5c708a4cda3a76446178e36203</originalsourceid><addsrcrecordid>eNp1kc1uEzEURi0EoqGw4AWQJTawmPb6bzxh10aBVKpEVSK2I8dz0ziaGQ-2p1VY9QG64Bl5EhxSWCCx8bV0zv1s6SPkNYMTBsBPNziccM1APCETprguhFDwlEyAayimTEyPyIsYtwAwlbx6To64VJVSICbkYea7YUwY3Hds6LDZRWed6akPDQaKfQq7n_c_ViZmGncxYUeTp0PA28zo4vwrDWhscrcmOd9T19Mh3zKLNGWS8tqdSxu6cr71N85Sc7OHH-hyg_Tqev5ldn1xnvP8Fm16SZ6tTRvx1eM8JsuP8-VsUVx-_nQxO7ssrORCFKVoNEdprVVWM87LdaWVWJVKasmBKwFGyyYzqIy0jRFGl1KWTFcoSg7imLw7xOZnv40YU925aLFtTY9-jDVTOQaEKllW3_6jbv0Y-vy5vQWyrPKRrfcHywYfY8B1PQTXmbCrGdT7hurcUP27oey-eUwcVx02f80_lWTh9CDcuRZ3_0-qF_OrQ-QvNeea9A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1540468404</pqid></control><display><type>article</type><title>Computerized physician order entry‐based system to prevent HBV reactivation in patients treated with biologic agents: The PRESCRIB project</title><source>MEDLINE</source><source>Wiley Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Sampedro, Blanca ; Hernández‐López, Cándido ; Ferrandiz, José Ramón ; Illaro, Aitziber ; Fábrega, Emilio ; Cuadrado, Antonio ; Iruzubieta, Paula ; Menéndez, Susana ; Cabezas, Joaquín ; Crespo, Javier</creator><creatorcontrib>Sampedro, Blanca ; Hernández‐López, Cándido ; Ferrandiz, José Ramón ; Illaro, Aitziber ; Fábrega, Emilio ; Cuadrado, Antonio ; Iruzubieta, Paula ; Menéndez, Susana ; Cabezas, Joaquín ; Crespo, Javier</creatorcontrib><description>Computerized physician order entry (CPOE) applications are widely used to prevent medical errors. In our center, a CPOE system has been in use since 2009 on both the inpatient and outpatient levels. A new and simple alert was introduced in the CPOE system to notify healthcare providers of the potential risk of viral reactivation when prescribing biological therapies, thereby facilitating the request for a serological profile (hepatitis B surface antigen [HBsAg], anti‐HBc, and anti‐HBs) in patients who have not had these tests. Between May 2012 and May 2013, a total of 1,076 patients undergoing biological treatment were included in the implementation of the CPOE in our hospital, resulting in the identification of 4 HBsAg‐positive and 69 anti‐HBc‐positive/HBsAg‐negative patients, two of them with positive viral loads. Since the implementation of this alert system, over 90% of patients who were prescribed a biological drug (BD) have undergone serological screening to detect hepatitis B virus (HBV) infection. The use of the alert system has increased the screening rate from less than 50% to 94% for HBsAg and from less than 30% to 85% for anti‐HBc in patients for whom a BD is prescribed. Six patients received prophylactic antiviral therapy. No patient had HBV reactivation. Conclusion: This study demonstrates the feasibility of implementing a CPOE system that has allowed our hospital to increase the rate of HBV screening. Its use has facilitated the identification of patients at high risk for HBV reactivation and permitted physicians to prescribe prophylactic measures according to current guidelines. (Hepatology 2014;106–113)</description><identifier>ISSN: 0270-9139</identifier><identifier>EISSN: 1527-3350</identifier><identifier>DOI: 10.1002/hep.27103</identifier><identifier>PMID: 24585503</identifier><identifier>CODEN: HPTLD9</identifier><language>eng</language><publisher>United States: Wolters Kluwer Health, Inc</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antiviral Agents - therapeutic use ; Biological Factors - adverse effects ; Child ; Feasibility Studies ; Female ; Hepatitis ; Hepatitis B Antibodies - blood ; Hepatitis B Surface Antigens - blood ; Hepatitis B, Chronic - epidemiology ; Hepatitis B, Chronic - immunology ; Hepatitis B, Chronic - prevention &amp; control ; Hepatology ; Hospitals ; Humans ; Immunosuppressive Agents - adverse effects ; Male ; Medical errors ; Medical Order Entry Systems - organization &amp; administration ; Middle Aged ; Order entry ; Physicians ; Practice Patterns, Physicians' - organization &amp; administration ; Prospective Studies ; Risk Factors ; Virus Activation - drug effects ; Virus Activation - immunology ; Young Adult</subject><ispartof>Hepatology (Baltimore, Md.), 2014-07, Vol.60 (1), p.106-113</ispartof><rights>2014 by the American Association for the Study of Liver Diseases</rights><rights>2014 by the American Association for the Study of Liver Diseases.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4233-63d72e4ccc5c71226f8753b65474202530a74d5c708a4cda3a76446178e36203</citedby><cites>FETCH-LOGICAL-c4233-63d72e4ccc5c71226f8753b65474202530a74d5c708a4cda3a76446178e36203</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhep.27103$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhep.27103$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24585503$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sampedro, Blanca</creatorcontrib><creatorcontrib>Hernández‐López, Cándido</creatorcontrib><creatorcontrib>Ferrandiz, José Ramón</creatorcontrib><creatorcontrib>Illaro, Aitziber</creatorcontrib><creatorcontrib>Fábrega, Emilio</creatorcontrib><creatorcontrib>Cuadrado, Antonio</creatorcontrib><creatorcontrib>Iruzubieta, Paula</creatorcontrib><creatorcontrib>Menéndez, Susana</creatorcontrib><creatorcontrib>Cabezas, Joaquín</creatorcontrib><creatorcontrib>Crespo, Javier</creatorcontrib><title>Computerized physician order entry‐based system to prevent HBV reactivation in patients treated with biologic agents: The PRESCRIB project</title><title>Hepatology (Baltimore, Md.)</title><addtitle>Hepatology</addtitle><description>Computerized physician order entry (CPOE) applications are widely used to prevent medical errors. In our center, a CPOE system has been in use since 2009 on both the inpatient and outpatient levels. A new and simple alert was introduced in the CPOE system to notify healthcare providers of the potential risk of viral reactivation when prescribing biological therapies, thereby facilitating the request for a serological profile (hepatitis B surface antigen [HBsAg], anti‐HBc, and anti‐HBs) in patients who have not had these tests. Between May 2012 and May 2013, a total of 1,076 patients undergoing biological treatment were included in the implementation of the CPOE in our hospital, resulting in the identification of 4 HBsAg‐positive and 69 anti‐HBc‐positive/HBsAg‐negative patients, two of them with positive viral loads. Since the implementation of this alert system, over 90% of patients who were prescribed a biological drug (BD) have undergone serological screening to detect hepatitis B virus (HBV) infection. The use of the alert system has increased the screening rate from less than 50% to 94% for HBsAg and from less than 30% to 85% for anti‐HBc in patients for whom a BD is prescribed. Six patients received prophylactic antiviral therapy. No patient had HBV reactivation. Conclusion: This study demonstrates the feasibility of implementing a CPOE system that has allowed our hospital to increase the rate of HBV screening. Its use has facilitated the identification of patients at high risk for HBV reactivation and permitted physicians to prescribe prophylactic measures according to current guidelines. (Hepatology 2014;106–113)</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Biological Factors - adverse effects</subject><subject>Child</subject><subject>Feasibility Studies</subject><subject>Female</subject><subject>Hepatitis</subject><subject>Hepatitis B Antibodies - blood</subject><subject>Hepatitis B Surface Antigens - blood</subject><subject>Hepatitis B, Chronic - epidemiology</subject><subject>Hepatitis B, Chronic - immunology</subject><subject>Hepatitis B, Chronic - prevention &amp; control</subject><subject>Hepatology</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Immunosuppressive Agents - adverse effects</subject><subject>Male</subject><subject>Medical errors</subject><subject>Medical Order Entry Systems - organization &amp; administration</subject><subject>Middle Aged</subject><subject>Order entry</subject><subject>Physicians</subject><subject>Practice Patterns, Physicians' - organization &amp; administration</subject><subject>Prospective Studies</subject><subject>Risk Factors</subject><subject>Virus Activation - drug effects</subject><subject>Virus Activation - immunology</subject><subject>Young Adult</subject><issn>0270-9139</issn><issn>1527-3350</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc1uEzEURi0EoqGw4AWQJTawmPb6bzxh10aBVKpEVSK2I8dz0ziaGQ-2p1VY9QG64Bl5EhxSWCCx8bV0zv1s6SPkNYMTBsBPNziccM1APCETprguhFDwlEyAayimTEyPyIsYtwAwlbx6To64VJVSICbkYea7YUwY3Hds6LDZRWed6akPDQaKfQq7n_c_ViZmGncxYUeTp0PA28zo4vwrDWhscrcmOd9T19Mh3zKLNGWS8tqdSxu6cr71N85Sc7OHH-hyg_Tqev5ldn1xnvP8Fm16SZ6tTRvx1eM8JsuP8-VsUVx-_nQxO7ssrORCFKVoNEdprVVWM87LdaWVWJVKasmBKwFGyyYzqIy0jRFGl1KWTFcoSg7imLw7xOZnv40YU925aLFtTY9-jDVTOQaEKllW3_6jbv0Y-vy5vQWyrPKRrfcHywYfY8B1PQTXmbCrGdT7hurcUP27oey-eUwcVx02f80_lWTh9CDcuRZ3_0-qF_OrQ-QvNeea9A</recordid><startdate>201407</startdate><enddate>201407</enddate><creator>Sampedro, Blanca</creator><creator>Hernández‐López, Cándido</creator><creator>Ferrandiz, José Ramón</creator><creator>Illaro, Aitziber</creator><creator>Fábrega, Emilio</creator><creator>Cuadrado, Antonio</creator><creator>Iruzubieta, Paula</creator><creator>Menéndez, Susana</creator><creator>Cabezas, Joaquín</creator><creator>Crespo, Javier</creator><general>Wolters Kluwer Health, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201407</creationdate><title>Computerized physician order entry‐based system to prevent HBV reactivation in patients treated with biologic agents: The PRESCRIB project</title><author>Sampedro, Blanca ; Hernández‐López, Cándido ; Ferrandiz, José Ramón ; Illaro, Aitziber ; Fábrega, Emilio ; Cuadrado, Antonio ; Iruzubieta, Paula ; Menéndez, Susana ; Cabezas, Joaquín ; Crespo, Javier</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4233-63d72e4ccc5c71226f8753b65474202530a74d5c708a4cda3a76446178e36203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Biological Factors - adverse effects</topic><topic>Child</topic><topic>Feasibility Studies</topic><topic>Female</topic><topic>Hepatitis</topic><topic>Hepatitis B Antibodies - blood</topic><topic>Hepatitis B Surface Antigens - blood</topic><topic>Hepatitis B, Chronic - epidemiology</topic><topic>Hepatitis B, Chronic - immunology</topic><topic>Hepatitis B, Chronic - prevention &amp; control</topic><topic>Hepatology</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Immunosuppressive Agents - adverse effects</topic><topic>Male</topic><topic>Medical errors</topic><topic>Medical Order Entry Systems - organization &amp; administration</topic><topic>Middle Aged</topic><topic>Order entry</topic><topic>Physicians</topic><topic>Practice Patterns, Physicians' - organization &amp; administration</topic><topic>Prospective Studies</topic><topic>Risk Factors</topic><topic>Virus Activation - drug effects</topic><topic>Virus Activation - immunology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sampedro, Blanca</creatorcontrib><creatorcontrib>Hernández‐López, Cándido</creatorcontrib><creatorcontrib>Ferrandiz, José Ramón</creatorcontrib><creatorcontrib>Illaro, Aitziber</creatorcontrib><creatorcontrib>Fábrega, Emilio</creatorcontrib><creatorcontrib>Cuadrado, Antonio</creatorcontrib><creatorcontrib>Iruzubieta, Paula</creatorcontrib><creatorcontrib>Menéndez, Susana</creatorcontrib><creatorcontrib>Cabezas, Joaquín</creatorcontrib><creatorcontrib>Crespo, Javier</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Hepatology (Baltimore, Md.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sampedro, Blanca</au><au>Hernández‐López, Cándido</au><au>Ferrandiz, José Ramón</au><au>Illaro, Aitziber</au><au>Fábrega, Emilio</au><au>Cuadrado, Antonio</au><au>Iruzubieta, Paula</au><au>Menéndez, Susana</au><au>Cabezas, Joaquín</au><au>Crespo, Javier</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Computerized physician order entry‐based system to prevent HBV reactivation in patients treated with biologic agents: The PRESCRIB project</atitle><jtitle>Hepatology (Baltimore, Md.)</jtitle><addtitle>Hepatology</addtitle><date>2014-07</date><risdate>2014</risdate><volume>60</volume><issue>1</issue><spage>106</spage><epage>113</epage><pages>106-113</pages><issn>0270-9139</issn><eissn>1527-3350</eissn><coden>HPTLD9</coden><abstract>Computerized physician order entry (CPOE) applications are widely used to prevent medical errors. In our center, a CPOE system has been in use since 2009 on both the inpatient and outpatient levels. A new and simple alert was introduced in the CPOE system to notify healthcare providers of the potential risk of viral reactivation when prescribing biological therapies, thereby facilitating the request for a serological profile (hepatitis B surface antigen [HBsAg], anti‐HBc, and anti‐HBs) in patients who have not had these tests. Between May 2012 and May 2013, a total of 1,076 patients undergoing biological treatment were included in the implementation of the CPOE in our hospital, resulting in the identification of 4 HBsAg‐positive and 69 anti‐HBc‐positive/HBsAg‐negative patients, two of them with positive viral loads. Since the implementation of this alert system, over 90% of patients who were prescribed a biological drug (BD) have undergone serological screening to detect hepatitis B virus (HBV) infection. The use of the alert system has increased the screening rate from less than 50% to 94% for HBsAg and from less than 30% to 85% for anti‐HBc in patients for whom a BD is prescribed. Six patients received prophylactic antiviral therapy. No patient had HBV reactivation. Conclusion: This study demonstrates the feasibility of implementing a CPOE system that has allowed our hospital to increase the rate of HBV screening. Its use has facilitated the identification of patients at high risk for HBV reactivation and permitted physicians to prescribe prophylactic measures according to current guidelines. (Hepatology 2014;106–113)</abstract><cop>United States</cop><pub>Wolters Kluwer Health, Inc</pub><pmid>24585503</pmid><doi>10.1002/hep.27103</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0270-9139
ispartof Hepatology (Baltimore, Md.), 2014-07, Vol.60 (1), p.106-113
issn 0270-9139
1527-3350
language eng
recordid cdi_proquest_miscellaneous_1542003561
source MEDLINE; Wiley Journals; EZB-FREE-00999 freely available EZB journals
subjects Adolescent
Adult
Aged
Aged, 80 and over
Antiviral Agents - therapeutic use
Biological Factors - adverse effects
Child
Feasibility Studies
Female
Hepatitis
Hepatitis B Antibodies - blood
Hepatitis B Surface Antigens - blood
Hepatitis B, Chronic - epidemiology
Hepatitis B, Chronic - immunology
Hepatitis B, Chronic - prevention & control
Hepatology
Hospitals
Humans
Immunosuppressive Agents - adverse effects
Male
Medical errors
Medical Order Entry Systems - organization & administration
Middle Aged
Order entry
Physicians
Practice Patterns, Physicians' - organization & administration
Prospective Studies
Risk Factors
Virus Activation - drug effects
Virus Activation - immunology
Young Adult
title Computerized physician order entry‐based system to prevent HBV reactivation in patients treated with biologic agents: The PRESCRIB project
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T05%3A24%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Computerized%20physician%20order%20entry%E2%80%90based%20system%20to%20prevent%20HBV%20reactivation%20in%20patients%20treated%20with%20biologic%20agents:%20The%20PRESCRIB%20project&rft.jtitle=Hepatology%20(Baltimore,%20Md.)&rft.au=Sampedro,%20Blanca&rft.date=2014-07&rft.volume=60&rft.issue=1&rft.spage=106&rft.epage=113&rft.pages=106-113&rft.issn=0270-9139&rft.eissn=1527-3350&rft.coden=HPTLD9&rft_id=info:doi/10.1002/hep.27103&rft_dat=%3Cproquest_cross%3E1542003561%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1540468404&rft_id=info:pmid/24585503&rfr_iscdi=true